ATE154931T1 - Morphinan-o-arylether - Google Patents
Morphinan-o-aryletherInfo
- Publication number
- ATE154931T1 ATE154931T1 AT93120498T AT93120498T ATE154931T1 AT E154931 T1 ATE154931 T1 AT E154931T1 AT 93120498 T AT93120498 T AT 93120498T AT 93120498 T AT93120498 T AT 93120498T AT E154931 T1 ATE154931 T1 AT E154931T1
- Authority
- AT
- Austria
- Prior art keywords
- alkyl
- formula
- hydrogen
- group
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/28—Morphinans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US113593A | 1993-01-06 | 1993-01-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE154931T1 true ATE154931T1 (de) | 1997-07-15 |
Family
ID=21694554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT93120498T ATE154931T1 (de) | 1993-01-06 | 1993-12-20 | Morphinan-o-arylether |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP0612730B1 (OSRAM) |
| JP (1) | JP2501298B2 (OSRAM) |
| KR (1) | KR940018094A (OSRAM) |
| CN (1) | CN1097006A (OSRAM) |
| AT (1) | ATE154931T1 (OSRAM) |
| AU (1) | AU681601B2 (OSRAM) |
| BR (1) | BR9400021A (OSRAM) |
| CA (1) | CA2110337A1 (OSRAM) |
| CZ (1) | CZ2294A3 (OSRAM) |
| DE (1) | DE69311887T2 (OSRAM) |
| DK (1) | DK0612730T3 (OSRAM) |
| ES (1) | ES2105061T3 (OSRAM) |
| FI (1) | FI940041A7 (OSRAM) |
| GR (1) | GR3024891T3 (OSRAM) |
| HU (2) | HUT66061A (OSRAM) |
| IL (1) | IL108247A (OSRAM) |
| MX (1) | MX9400177A (OSRAM) |
| NO (1) | NO940028D0 (OSRAM) |
| NZ (1) | NZ250580A (OSRAM) |
| PL (1) | PL175365B1 (OSRAM) |
| TW (1) | TW264473B (OSRAM) |
| UY (1) | UY23706A1 (OSRAM) |
| ZA (1) | ZA939806B (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9522176D0 (en) * | 1995-10-30 | 1996-01-03 | Iaf Biochem Int | Morphinan derivatives having neuroprotective activity |
| EP1394160A1 (en) * | 1996-06-13 | 2004-03-03 | SUMIKA FINE CHEMICALS Co., Ltd. | Process for preparing crystalline paroxetin hydrochloride |
| FR2752163B1 (fr) * | 1996-08-12 | 1998-10-30 | Pf Medicament | Utilisation de l'efaroxan pour la fabricaton de medicament destine au traitement de la maladie de huntington |
| GB9706753D0 (en) * | 1997-04-03 | 1997-05-21 | Pharmacia & Upjohn Spa | Aralkoxy-morphinan derivatives |
| KR100425881B1 (ko) * | 2001-03-14 | 2004-04-03 | 고광호 | 신규한 몰피난 유도체 |
| AU2003234621A1 (en) * | 2002-05-17 | 2003-12-02 | Jenken Biosciences, Inc. | Opioid and opioid-like compounds and uses thereof |
| DE10229842A1 (de) * | 2002-07-03 | 2004-02-05 | Helmut Prof. Dr. Schmidhammer | Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung |
| US20040204862A1 (en) | 2003-04-11 | 2004-10-14 | Wainer Irving W. | Computer-based model for identification and characterization for non-competitive inhibitors of nicotinic acetylcholine receptors and related ligand-gated ion channel receptors |
| US8017622B2 (en) | 2003-05-16 | 2011-09-13 | Jenken Biosciences, Inc. | Opioid and opioid-like compounds and uses thereof |
| US8436174B2 (en) * | 2009-02-23 | 2013-05-07 | Mallinckrodt Llc | (+)-morphinanium quaternary salts and processes for their production |
| CN103044327B (zh) * | 2013-01-07 | 2014-12-17 | 苏州立新制药有限公司 | 一种右美沙芬的制备方法 |
| EP4166141A1 (en) * | 2014-09-14 | 2023-04-19 | Avanir Pharmaceuticals, Inc. | Combinations of deuterated dextromethorphan and quinidine for the treatment of agitation and aggression in alzheimer's dementia |
| WO2016138103A1 (en) * | 2015-02-25 | 2016-09-01 | Alkermes, Inc. | Treatments for alzheimer's related diseases and disorders |
| AU2021332768B2 (en) * | 2020-08-28 | 2024-04-18 | Nippon Chemiphar Co., Ltd. | Method for preparing morphinan derivative having diaryl ether skeleton using novel copper catalyst |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI773636A7 (fi) * | 1976-12-06 | 1978-06-07 | Hoffmann La Roche | Nya fenylderivat |
| US4113729A (en) * | 1976-12-06 | 1978-09-12 | Hoffmann-La Roche Inc. | 3-Phenoxymorphinans and derivatives thereof |
| US4806543A (en) * | 1986-11-25 | 1989-02-21 | Board Of Trustees Of The Leland Stanford Junior University | Method and compositions for reducing neurotoxic injury |
-
1993
- 1993-11-25 TW TW082109942A patent/TW264473B/zh active
- 1993-11-30 CA CA002110337A patent/CA2110337A1/en not_active Abandoned
- 1993-12-20 AT AT93120498T patent/ATE154931T1/de not_active IP Right Cessation
- 1993-12-20 EP EP93120498A patent/EP0612730B1/en not_active Expired - Lifetime
- 1993-12-20 DE DE69311887T patent/DE69311887T2/de not_active Expired - Fee Related
- 1993-12-20 ES ES93120498T patent/ES2105061T3/es not_active Expired - Lifetime
- 1993-12-20 DK DK93120498.6T patent/DK0612730T3/da active
- 1993-12-23 NZ NZ250580A patent/NZ250580A/en unknown
- 1993-12-30 JP JP5354172A patent/JP2501298B2/ja not_active Expired - Lifetime
- 1993-12-30 ZA ZA939806A patent/ZA939806B/xx unknown
- 1993-12-31 IL IL108247A patent/IL108247A/en not_active IP Right Cessation
- 1993-12-31 AU AU52807/93A patent/AU681601B2/en not_active Ceased
- 1993-12-31 UY UY23706A patent/UY23706A1/es unknown
-
1994
- 1994-01-03 MX MX9400177A patent/MX9400177A/es not_active IP Right Cessation
- 1994-01-03 HU HU9400002A patent/HUT66061A/hu unknown
- 1994-01-04 NO NO940028A patent/NO940028D0/no unknown
- 1994-01-04 KR KR1019940000067A patent/KR940018094A/ko not_active Ceased
- 1994-01-05 BR BR9400021A patent/BR9400021A/pt not_active Application Discontinuation
- 1994-01-05 CZ CZ9422A patent/CZ2294A3/cs unknown
- 1994-01-05 PL PL94301784A patent/PL175365B1/pl unknown
- 1994-01-05 FI FI940041A patent/FI940041A7/fi unknown
- 1994-01-05 CN CN94100181A patent/CN1097006A/zh active Pending
-
1995
- 1995-06-19 HU HU95P/P00253P patent/HU211290A9/hu unknown
-
1997
- 1997-09-30 GR GR970402538T patent/GR3024891T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR9400021A (pt) | 1994-07-26 |
| AU5280793A (en) | 1994-07-14 |
| GR3024891T3 (en) | 1998-01-30 |
| TW264473B (OSRAM) | 1995-12-01 |
| DE69311887T2 (de) | 1998-01-15 |
| ES2105061T3 (es) | 1997-10-16 |
| CN1097006A (zh) | 1995-01-04 |
| NZ250580A (en) | 1996-07-26 |
| EP0612730B1 (en) | 1997-07-02 |
| FI940041L (fi) | 1994-07-07 |
| HU211290A9 (en) | 1995-11-28 |
| DK0612730T3 (da) | 1998-02-02 |
| FI940041A0 (fi) | 1994-01-05 |
| FI940041A7 (fi) | 1994-07-07 |
| PL301784A1 (en) | 1994-07-11 |
| MX9400177A (es) | 1994-07-29 |
| NO940028D0 (no) | 1994-01-04 |
| CA2110337A1 (en) | 1994-07-07 |
| JP2501298B2 (ja) | 1996-05-29 |
| NO940028L (OSRAM) | 1994-07-07 |
| HUT66061A (en) | 1994-09-28 |
| EP0612730A1 (en) | 1994-08-31 |
| IL108247A (en) | 1998-02-22 |
| CZ2294A3 (en) | 1994-07-13 |
| KR940018094A (ko) | 1994-08-16 |
| PL175365B1 (pl) | 1998-12-31 |
| IL108247A0 (en) | 1994-04-12 |
| AU681601B2 (en) | 1997-09-04 |
| DE69311887D1 (de) | 1997-08-07 |
| ZA939806B (en) | 1994-07-06 |
| UY23706A1 (es) | 1994-06-05 |
| HU9400002D0 (en) | 1994-05-30 |
| JPH06316564A (ja) | 1994-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69311887D1 (de) | Morphinan-O-Arylether | |
| GB9122590D0 (en) | Pharmaceutical compounds | |
| OA09391A (en) | "Isoxazole derivatives". | |
| FI934144A0 (fi) | Morfinanderivat och medicinsk anvaendning | |
| DE69331414D1 (de) | Depsipeptide, herstellung und anwendung | |
| EP1310494A4 (en) | PPAR-DELTA ACTIVATORS | |
| HU9301866D0 (en) | Benzoxa-condensed-ring-compounds and medical preparatives containing these compounds and processes for production of these compounds and of pharmaceutical composition | |
| NZ248099A (en) | Use of spiro-oxathiolane quinuclidine derivatives for treating sjoegren syndrome | |
| BR9103665A (pt) | Composicao inseticida e processo para a producao de um composto | |
| PL288141A1 (en) | Fungicide | |
| HUT64073A (en) | Process for producing 13-(substituted thiol)-acetoxymilbemycin derivatives and insecticidal and acaricidal composition comprising such compounds | |
| GR3020987T3 (en) | Thiazolidinedione hypoglycemic agents. | |
| ATE105565T1 (de) | Pradimicinderivate. | |
| EP0447812A3 (en) | Use of a dihydropyridine to improve the inner ear blood circulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |